Category: Biologic therapy

The global self-administered biologics market was valued at USD 94.06 billion in 2024 and is projected to grow significantly [1.2.1, 1.2.2]. For many patients with chronic conditions, the answer to 'Can biologics be self-administered?' is increasingly yes, offering new flexibility in treatment.

According to FDA approval data, the biologic medication Tezspire (tezepelumab-ekko) is an add-on maintenance treatment for adults and children aged 12 and older with severe, uncontrolled asthma. Unlike other biologics that target specific downstream inflammatory pathways, Tezspire works by blocking a key protein called thymic stromal lymphopoietin (TSLP) early in the inflammatory cascade, providing broader efficacy for various asthma types.